Sucampo Pharmaceuticals, an international biopharmaceutical company, has announced that Jan Smilek, chief financial officer (CFO) and vice president, finance, has resigned to pursue other opportunities. The company will initiate search for a new CFO.
Smilek joined Sucampo in February 2008 as vice president of finance and corporate controller. In August 2008, he was appointed acting CFO and in December 2009 he was appointed CFO. Prior to joining Sucampo, Smilek was the senior director of finance at Vanda Pharmaceuticals.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.